Mitsubishi UFJ Trust & Banking Corp Cuts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Mitsubishi UFJ Trust & Banking Corp lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 77,461 shares of the biopharmaceutical company’s stock after selling 8,273 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Alnylam Pharmaceuticals were worth $35,322,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 1.8% during the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after buying an additional 240,534 shares during the period. Geode Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after acquiring an additional 75,936 shares in the last quarter. Orbis Allan Gray Ltd boosted its position in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $662,837,000. Finally, American Century Companies Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock valued at $584,957,000 after acquiring an additional 33,411 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $357.98 on Monday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The firm has a market capitalization of $47.29 billion, a price-to-earnings ratio of 1,491.58 and a beta of 0.32. The stock’s 50-day simple moving average is $409.91 and its 200-day simple moving average is $423.98.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of recent research reports. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Jefferies Financial Group reduced their target price on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Piper Sandler restated an “overweight” rating and issued a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Oppenheimer initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective on the stock. Finally, Raymond James Financial reissued an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $485.21.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the transaction, the chief executive officer owned 78,411 shares in the company, valued at approximately $28,452,215.46. This represents a 10.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 56,955 shares of company stock worth $24,072,733 in the last 90 days. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.